{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:46:57Z","timestamp":1793666817971,"version":"4.5.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is the second most common progressive neurodegenerative disorder associated with increased oxidative stress, the underlying vital process contributing to cell death. Tanshinone IIA (TAN) is a phytomedicine with a documented activity in treating many CNS disorders, particularly PD owing to its unique anti-inflammatory and antioxidant effect. However, its clinical utility is limited by its poor aqueous solubility, short half-life, and hence low concentration reaching targeted cells. This work aimed to develop a biocompatible chitosan-coated nanostructured lipid carriers (CS-NLCs) for effective brain delivery of TAN for PD management. The proposed nanosystem was successfully prepared using a simple melt-emulsification ultra-sonication method, optimized and characterized both in vitro and in vivo in a rotenone-induced PD rat model. The developed TAN-loaded CS-NLCs (CS-TAN-NLCs) showed good colloidal properties (size\u2009\u2264\u2009200\u00a0nm, PDI\u2009\u2264\u20090.2, and \u03b6-potential\u2009+\u200920\u00a0mV) and high drug entrapment efficiency (&gt;\u200997%) with sustained release profile for 24\u00a0h. Following intranasal administration, CS-TAN-NLCs succeeded to achieve a remarkable antiparkinsonian and antidepressant effect in diseased animals compared to both the uncoated TAN-NLCs and free TAN suspension as evidenced by the conducted behavioral tests and improved histopathological findings. Furthermore, biochemical evaluation of oxidative stress along with inflammatory markers, nuclear factor-kabba \u03b2 (NF-K\u03b2) and cathepsin B further confirmed the potential of the CS-TAN-NLCs in enhancing brain delivery and hence the therapeutic effect of TAN of treatment of PD. Accordingly, CS-TAN-NLCs could be addressed as a promising nano-platform for the effective management of PD.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-023-01407-7","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:02:22Z","timestamp":1692453742000},"page":"400-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Chitosan-coated nanostructured lipid carriers for effective brain delivery of Tanshinone IIA in Parkinson\u2019s disease: interplay between nuclear factor-kappa \u03b2 and cathepsin B"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-6219","authenticated-orcid":false,"given":"Donia M.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8773-5365","authenticated-orcid":false,"given":"Amal H.","family":"El-Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-5164","authenticated-orcid":false,"given":"Eman A.","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1312-5350","authenticated-orcid":false,"given":"Basant A.","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4363-4698","authenticated-orcid":false,"given":"Asmaa A.","family":"Ashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"1407_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijbiomac.2017.12.056","volume":"109","author":"R Raj","year":"2018","unstructured":"Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol. 2018;109:27\u201335.","journal-title":"Int J Biol Macromol"},{"key":"1407_CR2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40266-022-00942-1","volume":"39","author":"S Prange","year":"2022","unstructured":"Prange S, Klinger H, Laurencin C, Danaila T, Thobois S. Depression in patients with Parkinson\u2019s disease: current understanding of its neurobiology and implications for treatment. Drugs Aging. 2022;39:417\u201339.","journal-title":"Drugs Aging"},{"key":"1407_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36:1\u201312.","journal-title":"Clin Geriatr Med"},{"key":"1407_CR4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1080\/10717544.2022.2058651","volume":"29","author":"Y Agrawal","year":"2022","unstructured":"Agrawal Y, Patil K, Mahajan H, Potdar M, Joshi P, Nakhate K, et al. In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach. Drug Deliv. 2022;29:1112\u201321.","journal-title":"Drug Deliv"},{"key":"1407_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105661","volume":"169","author":"L Subedi","year":"2021","unstructured":"Subedi L, Gaire BP. Tanshinone IIA: a phytochemical as a promising drug candidate for neurodegenerative diseases. Pharmacol Res. 2021;169: 105661.","journal-title":"Pharmacol Res"},{"key":"1407_CR6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2014.11.026","volume":"348","author":"B Ren","year":"2015","unstructured":"Ren B, Zhang YX, Zhou HX, Sun FW, Zhang ZF, Wei Z, et al. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson\u2019s disease. J Neurol Sci. 2015;348:142\u201352.","journal-title":"J Neurol Sci"},{"key":"1407_CR7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4314\/tjpr.v18i5.15","volume":"18","author":"J Zhang","year":"2019","unstructured":"Zhang J, Wang Y, Ji X, Shu Z. Tanshinone IIA protects against dopaminergic neuron degeneration via regulation of DJ-1 and Nrf2\/HO-1 pathways in a rodent model of Parkinson\u2019s disease. Trop J Pharm Res. 2019;18:1017\u201325.","journal-title":"Trop J Pharm Res"},{"key":"1407_CR8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119598","volume":"586","author":"AA Ashour","year":"2020","unstructured":"Ashour AA, Ramadan AA, Abdelmonsif DA, El-Kamel AH. Enhanced oral bioavailability of Tanshinone IIA using lipid nanocapsules: formulation, in-vitro appraisal and pharmacokinetics. Int J Pharm. 2020;586: 119598.","journal-title":"Int J Pharm"},{"key":"1407_CR9","first-page":"7422","volume":"13","author":"J Wang","year":"2021","unstructured":"Wang J, Cai J, Wang X, Zhu G, Feng Y, Chen H, et al. Erratum: An injectable liposome for sustained release of tanshinone IIA to the treatment of acute blunt muscle injury by augmenting autophagy and alleviating oxidative stress. Am J Transl Res. 2021;13:7422\u20134.","journal-title":"Am J Transl Res"},{"key":"1407_CR10","volume":"27","author":"WD Lee","year":"2016","unstructured":"Lee WD, Liang YJ, Chen BH. Effects of tanshinone nanoemulsion and extract on inhibition of lung cancer cells A549. Nanotechnology. 2016;27: 495101.","journal-title":"Nanotechnology"},{"key":"1407_CR11","volume":"155","author":"RM El-Moslemany","year":"2022","unstructured":"El-Moslemany RM, El-Kamel AH, Allam EA, Khalifa HM, Hussein A, Ashour AA. Tanshinone IIA loaded bioactive nanoemulsion for alleviation of lipopolysaccharide induced acute lung injury via inhibition of endothelial glycocalyx shedding. Biomed Pharmacother. 2022;155: 113666.","journal-title":"Biomed Pharmacother"},{"key":"1407_CR12","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.2147\/IJN.S331690","volume":"16","author":"AA Ashour","year":"2021","unstructured":"Ashour AA, El-Kamel AH, Abdelmonsif DA, Khalifa HM, Ramadan AA. Modified lipid nanocapsules for targeted tanshinone IIA delivery in liver fibrosis. Int J Nanomed. 2021;16:8013\u201333.","journal-title":"Int J Nanomed"},{"key":"1407_CR13","first-page":"2449","volume":"47","author":"FN Chen","year":"2022","unstructured":"Chen FN, Wang XL, Xu RR, Wang XJ. Ruan JH Preparation of tanshinone IIA-glycyrrhetinic acid solid lipid nanoparticles and its inhibitory effect on acne. Zhongguo Zhong Yao Za Zhi. 2022;47:2449\u201356.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"1407_CR14","first-page":"1421","volume":"44","author":"WL Zhang","year":"2009","unstructured":"Zhang WL, Liu JP, Liu XX, Chen ZQ. Stealth tanshinone IIA-loaded solid lipid nanoparticles: effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats. Yao Xue Xue Bao. 2009;44:1421\u20138.","journal-title":"Yao Xue Xue Bao"},{"key":"1407_CR15","unstructured":"Zheng J, Shen CY, Pang JY, Xu FC, Liao WB, Hu CX, et al. Preparation of tanshinone IIA loaded nanostructured lipid carrier and its in vitro transdermal permeation characteristics. Zhongguo Zhong Yao Za Zhi. 2016;41:3232\u20138."},{"key":"1407_CR16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s11064-021-03488-7","volume":"47","author":"TT Nguyen","year":"2022","unstructured":"Nguyen TT, Nguyen TTD, Tran NM, Van Vo G. Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders. Neurochem Res. 2022;47:552\u201373.","journal-title":"Neurochem Res"},{"key":"1407_CR17","doi-asserted-by":"crossref","unstructured":"Pottoo FH, Sharma S, Javed MN, Barkat MA, Harshita, Alam MS, et al. Lipid-based nanoformulations in the treatment of neurological disorders. Drug Metab Rev. 2020;52:185\u2013204.","DOI":"10.1080\/03602532.2020.1726942"},{"key":"1407_CR18","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1166\/jbn.2016.2313","volume":"12","author":"O Gartziandia","year":"2016","unstructured":"Gartziandia O, Herr\u00e1n E, Ruiz-Ortega JA, Miguelez C, Igartua M, Lafuente JV, et al. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson\u2019s disease. J Biomed Nanotechnol. 2016;12:2220\u201330.","journal-title":"J Biomed Nanotechnol"},{"key":"1407_CR19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12640-018-9978-z","volume":"35","author":"V Manigandan","year":"2019","unstructured":"Manigandan V, Nataraj J, Karthik R, Manivasagam T, Saravanan R, Thenmozhi AJ, et al. Low molecular weight sulfated chitosan: neuroprotective effect on rotenone-induced in vitro Parkinson\u2019s disease. Neurotox Res. 2019;35:505\u201315.","journal-title":"Neurotox Res"},{"key":"1407_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117435","volume":"254","author":"MN Sardoiwala","year":"2021","unstructured":"Sardoiwala MN, Karmakar S, Choudhury SR. Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson\u2019s disease via PP2A-EzH2 signaling in vitro and ex vivo. Carbohydr Polym. 2021;254: 117435.","journal-title":"Carbohydr Polym"},{"key":"1407_CR21","volume":"196","author":"YC Pyo","year":"2020","unstructured":"Pyo YC, Tran P, Kim DH, Park JS. Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy. Colloids Surf B Biointerf. 2020;196: 111331.","journal-title":"Colloids Surf B Biointerf"},{"key":"1407_CR22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","volume":"134","author":"O Gartziandia","year":"2015","unstructured":"Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerf. 2015;134:304\u201313.","journal-title":"Colloids Surf B Biointerf"},{"key":"1407_CR23","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.2217\/nnm-2016-0236","volume":"11","author":"MS Freag","year":"2016","unstructured":"Freag MS, Elnaggar YS, Abdelmonsif DA, Abdallah OY. Layer-by-layer-coated lyotropic liquid crystalline nanoparticles for active tumor targeting of rapamycin. Nanomedicine (Lond). 2016;11:2975\u201396.","journal-title":"Nanomedicine (Lond)"},{"key":"1407_CR24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. Aaps j. 2010;12:263\u201371.","journal-title":"Aaps j"},{"key":"1407_CR25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s13346-020-00800-w","volume":"11","author":"CT Uppuluri","year":"2021","unstructured":"Uppuluri CT, Ravi PR, Dalvi AV, Shaikh SS, Kale SR. Piribedil loaded thermo-responsive nasal in situ gelling system for enhanced delivery to the brain: formulation optimization, physical characterization, and in vitro and in vivo evaluation. Drug Deliv Transl Res. 2021;11:909\u201326.","journal-title":"Drug Deliv Transl Res"},{"key":"1407_CR26","volume":"18","author":"DE Ali","year":"2023","unstructured":"Ali DE, Bassam SM, Elatrebi S, Habiba ES, Allam EA, Omar EM, et al. HR LC-MS\/MS metabolomic profiling of Yucca aloifolia fruit and the potential neuroprotective effect on rotenone-induced Parkinson\u2019s disease in rats. PLoS ONE. 2023;18: e0282246.","journal-title":"PLoS ONE"},{"key":"1407_CR27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0076-6879(90)86135-I","volume":"186","author":"HH Draper","year":"1990","unstructured":"Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421\u201331.","journal-title":"Methods Enzymol"},{"key":"1407_CR28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3389\/fnmol.2020.00084","volume":"13","author":"SH El-Ghaiesh","year":"2020","unstructured":"El-Ghaiesh SH, Bahr HI, Ibrahiem AT, Ghorab D, Alomar SY, Farag NE, et al. Metformin protects from rotenone-induced nigrostriatal neuronal death in adult mice by activating AMPK-FOXO3 signaling and mitigation of angiogenesis. Front Mol Neurosci. 2020;13:84.","journal-title":"Front Mol Neurosci"},{"key":"1407_CR29","volume":"619","author":"EMM Shehata","year":"2022","unstructured":"Shehata EMM, Gowayed MA, El-Ganainy SO, Sheta E, Elnaggar YSR, Abdallah OY. Pectin coated nanostructured lipid carriers for targeted piperine delivery to hepatocellular carcinoma. Int J Pharm. 2022;619: 121712.","journal-title":"Int J Pharm"},{"key":"1407_CR30","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1166\/jbn.2018.2581","volume":"14","author":"H Wei","year":"2018","unstructured":"Wei H, Liu T, Jiang N, Zhou K, Yang K, Ning W, et al. A novel delivery system of cyclovirobuxine D for brain targeting: angiopep-conjugated polysorbate 80-coated liposomes via intranasal administration. J Biomed Nanotechnol. 2018;14:1252\u201362.","journal-title":"J Biomed Nanotechnol"},{"key":"1407_CR31","doi-asserted-by":"crossref","unstructured":"Hassan DH, Shohdy JN, El-Setouhy DA, El-Nabarawi M, Naguib MJ. Compritol-based nanostrucutured lipid carriers (NLCs) for augmentation of zolmitriptan bioavailability via the transdermal route: in vitro optimization, ex vivo permeation, in vivo pharmacokinetic study. Pharmaceutics. 2022;14.","DOI":"10.3390\/pharmaceutics14071484"},{"key":"1407_CR32","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2022.130039","volume":"654","author":"FL L\u00fcdtke","year":"2022","unstructured":"L\u00fcdtke FL, Stahl MA, Grimaldi R, Cardoso LP, Gigante ML, Ribeiro APB. High oleic sunflower oil and fully hydrogenated soybean oil nanostructured lipid carriers: development and characterization. Colloids Surf: Physicochem Eng Asp. 2022;654: 130039.","journal-title":"Colloids Surf: Physicochem Eng Asp"},{"key":"1407_CR33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejpb.2022.09.009","volume":"179","author":"EDP Almeida","year":"2022","unstructured":"Almeida EDP, Santos Silva LA, de Araujo GRS, Montalv\u00e3o MM, Matos SS, da Cunha Gonsalves JKM, et al. Chitosan-functionalized nanostructured lipid carriers containing chloroaluminum phthalocyanine for photodynamic therapy of skin cancer. Euro J Pharm Biopharm. 2022;179:221\u201331.","journal-title":"Euro J Pharm Biopharm"},{"key":"1407_CR34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ijbiomac.2022.10.168","volume":"224","author":"DS Sharma","year":"2023","unstructured":"Sharma DS, Wadhwa S, Gulati M, Kumar B, Chitranshi N, Gupta VK, et al. Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: a new dimension to an anticancer drug. Int J Biol Macromol. 2023;224:810\u201330.","journal-title":"Int J Biol Macromol"},{"key":"1407_CR35","doi-asserted-by":"crossref","unstructured":"Bhaskaran NA, Jitta SR, Salwa, Cheruku S, Kumar N, Kumar L. Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: preparation, in-vitro and in-vivo evaluations. Int J Biol Macromol. 2022;211:301\u201315.","DOI":"10.1016\/j.ijbiomac.2022.05.060"},{"key":"1407_CR36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118447","volume":"567","author":"M Zewail","year":"2019","unstructured":"Zewail M, Nafee N, Helmy MW, Boraie N. Coated nanostructured lipid carriers targeting the joints - an effective and safe approach for the oral management of rheumatoid arthritis. Int J Pharm. 2019;567: 118447.","journal-title":"Int J Pharm"},{"key":"1407_CR37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.34172\/apb.2020.021","volume":"10","author":"I Chauhan","year":"2020","unstructured":"Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery. Adv Pharm Bull. 2020;10:150\u201365.","journal-title":"Adv Pharm Bull"},{"key":"1407_CR38","doi-asserted-by":"crossref","unstructured":"Shawky S, Makled S, Awaad A, Boraie N. Quercetin loaded cationic solid lipid nanoparticles in a mucoadhesive in situ gel-a novel intravesical therapy tackling bladder cancer. Pharmaceutics. 2022;14.","DOI":"10.3390\/pharmaceutics14112527"},{"key":"1407_CR39","volume":"232","author":"RK Eid","year":"2020","unstructured":"Eid RK, Ashour DS, Essa EA, El Maghraby GM, Arafa MF. Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis. Carb Polym. 2020;232: 115826.","journal-title":"Carb Polym"},{"key":"1407_CR40","volume":"196","author":"Y-C Pyo","year":"2020","unstructured":"Pyo Y-C, Tran P, Kim D-H, Park J-S. Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy. Colloids Surf B: Biointerf. 2020;196: 111331.","journal-title":"Colloids Surf B: Biointerf"},{"key":"1407_CR41","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3109\/10717544.2015.1048491","volume":"23","author":"H Jiang","year":"2016","unstructured":"Jiang H, Pei L, Liu N, Li J, Li Z, Zhang S. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy. Drug Deliv. 2016;23:1379\u201382.","journal-title":"Drug Deliv"},{"key":"1407_CR42","doi-asserted-by":"crossref","unstructured":"Crowe TP, Hsu WH. Evaluation of recent intranasal drug delivery systems to the central nervous system. Pharmaceutics. 2022;14.","DOI":"10.3390\/pharmaceutics14030629"},{"key":"1407_CR43","doi-asserted-by":"crossref","unstructured":"Noorulla KM, Yasir M, Muzaffar F,\u00a0Roshan S, Ghoneim MM, Almurshedi AS, et al. Intranasal delivery of chitosan decorated nanostructured lipid carriers of Buspirone for brain targeting: formulation development, optimization and in-vivo preclinical evaluation. J Drug Deliv Sci Technol. 2022;67:102939.","DOI":"10.1016\/j.jddst.2021.102939"},{"key":"1407_CR44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40005-017-0342-8","volume":"48","author":"V Pokharkar","year":"2018","unstructured":"Pokharkar V, Patil-Gadhe A, Kaur G. Physicochemical and pharmacokinetic evaluation of rosuvastatin loaded nanostructured lipid carriers: influence of long- and medium-chain fatty acid mixture. J Pharm Investig. 2018;48:465\u201376.","journal-title":"J Pharm Investig"},{"key":"1407_CR45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4103\/ijp.IJP_384_20","volume":"54","author":"KV Abhangi","year":"2022","unstructured":"Abhangi KV, Patel JI. Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson\u2019s disease. Indian J Pharmacol. 2022;54:46\u201350.","journal-title":"Indian J Pharmacol"},{"key":"1407_CR46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.12965\/jer.1734966.483","volume":"13","author":"MS Shin","year":"2017","unstructured":"Shin MS, Kim TW, Lee JM, Sung YH, Lim BV. Treadmill exercise alleviates depressive symptoms in rotenone-induced Parkinson disease rats. J Exerc Rehabil. 2017;13:124\u20139.","journal-title":"J Exerc Rehabil"},{"key":"1407_CR47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molbrainres.2004.11.007","volume":"134","author":"CM Testa","year":"2005","unstructured":"Testa CM, Sherer TB, Greenamyre JT. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res. 2005;134:109\u201318.","journal-title":"Brain Res Mol Brain Res"},{"key":"1407_CR48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuint.2006.02.003","volume":"49","author":"K Radad","year":"2006","unstructured":"Radad K, Rausch WD, Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem Int. 2006;49:379\u201386.","journal-title":"Neurochem Int"},{"key":"1407_CR49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12906-019-2738-7","volume":"20","author":"T Wang","year":"2020","unstructured":"Wang T, Li C, Han B, Wang Z, Meng X, Zhang L, et al. Neuroprotective effects of Danshensu on rotenone-induced Parkinson\u2019s disease models in vitro and in vivo. BMC Complement Med Ther. 2020;20:20.","journal-title":"BMC Complement Med Ther"},{"key":"1407_CR50","doi-asserted-by":"crossref","unstructured":"Sherawat K, Mehan S. Tanshinone-IIA mediated neuroprotection by modulating neuronal pathways. Naunyn Schmiedebergs Arch Pharmacol. 2023;396:1647\u201367.","DOI":"10.1007\/s00210-023-02476-8"},{"key":"1407_CR51","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1208\/s12249-018-1180-3","volume":"19","author":"SM Etman","year":"2018","unstructured":"Etman SM, Elnaggar YSR, Abdelmonsif DA, Abdallah OY. Oral brain-targeted microemulsion for enhanced piperine delivery in Alzheimer\u2019s disease therapy: in vitro appraisal, in vivo activity, and nanotoxicity. AAPS PharmSciTech. 2018;19:3698\u2013711.","journal-title":"AAPS PharmSciTech"},{"key":"1407_CR52","doi-asserted-by":"crossref","unstructured":"Witika BA, Poka MS, Demana PH, Matafwali SK, Melamane S, Malungelo Khamanga SM, et al. Lipid-based nanocarriers for neurological disorders: a review of the state-of-the-art and therapeutic success to date. Pharmaceutics. 2022;14.","DOI":"10.3390\/pharmaceutics14040836"},{"key":"1407_CR53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/10826076.2017.1343735","volume":"40","author":"N Ahmad","year":"2017","unstructured":"Ahmad N. Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of Parkinson\u2019s disease. J Liquid Chromatogr Related Technol. 2017;40:677\u201390.","journal-title":"J Liquid Chromatogr Related Technol"},{"key":"1407_CR54","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.xphs.2020.04.007","volume":"109","author":"LH Salem","year":"2020","unstructured":"Salem LH, El-Feky GS, Fahmy RH, El Gazayerly ON, Abdelbary A. Coated lipidic nanoparticles as a new strategy for enhancing nose-to-brain delivery of a hydrophilic drug molecule. J Pharm Sci. 2020;109:2237\u201351.","journal-title":"J Pharm Sci"},{"key":"1407_CR55","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cnr.2006.09.006","volume":"6","author":"RL Mosley","year":"2006","unstructured":"Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, et al. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson\u2019s disease. Clin Neurosci Res. 2006;6:261\u201381.","journal-title":"Clin Neurosci Res"},{"key":"1407_CR56","volume":"2011","author":"PM Flood","year":"2011","unstructured":"Flood PM, Qian L, Peterson LJ, Zhang F, Shi JS, Gao HM, et al. Transcriptional factor NF-\u03baB as a target for therapy in Parkinson\u2019s disease. Parkinsons Dis. 2011;2011: 216298.","journal-title":"Parkinsons Dis"},{"key":"1407_CR57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijbiomac.2020.11.207","volume":"167","author":"N Nehal","year":"2021","unstructured":"Nehal N, Nabi B, Rehman S, Pathak A, Iqubal A, Khan SA, et al. Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson\u2019s disease: formulation perspective and in vitro and in vivo assessment. Int J Biol Macromol. 2021;167:605\u201319.","journal-title":"Int J Biol Macromol"},{"key":"1407_CR58","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/jmf.2017.4078","volume":"21","author":"UJ Jung","year":"2018","unstructured":"Jung UJ, Kim SR. Beneficial effects of flavonoids against Parkinson\u2019s disease. J Med Food. 2018;21:421\u201332.","journal-title":"J Med Food"},{"key":"1407_CR59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/1673-5374.264444","volume":"15","author":"H Nakanishi","year":"2020","unstructured":"Nakanishi H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. Neural Regen Res. 2020;15:25\u20139.","journal-title":"Neural Regen Res"},{"key":"1407_CR60","volume":"15","author":"L Zhang","year":"2022","unstructured":"Zhang L, Li Q. Neuroprotective effects of tanshinone IIA in experimental model of Parkinson disease in rats. Arab JChem. 2022;15: 104269.","journal-title":"Arab JChem"},{"key":"1407_CR61","volume":"13","author":"W Sun","year":"2021","unstructured":"Sun W, Zheng J, Ma J, Wang Z, Shi X, Li M, et al. Increased plasma heme oxygenase-1 levels in patients with early-stage Parkinson\u2019s disease. Front Aging Neurosci. 2021;13: 621508.","journal-title":"Front Aging Neurosci"},{"key":"1407_CR62","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/neurosci3020020","volume":"3","author":"M Cressatti","year":"2022","unstructured":"Cressatti M, Schipper HM. Dysregulation of a heme oxygenase\u2013synuclein axis in Parkinson disease. NeuroSci. 2022;3:284\u201399.","journal-title":"NeuroSci"},{"key":"1407_CR63","first-page":"51","volume-title":"Genetics","author":"G Alam","year":"2020","unstructured":"Alam G, Richardson JR. Chapter 4 - Regulation of tyrosine hydroxylase: relevance to Parkinson\u2019s disease. In: Martin CR, Preedy VR, editors. Genetics. Neurology, Behavior, and Diet in Parkinson\u2019s Disease: Academic Press; 2020. p. 51\u201366."},{"key":"1407_CR64","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.14202\/vetworld.2018.1250-1254","volume":"11","author":"YK Adi","year":"2018","unstructured":"Adi YK, Widayanti R, Pangestiningsih TW. n-Propanol extract of boiled and fermented koro benguk (Mucuna pruriens seed) shows a neuroprotective effect in paraquat dichloride-induced Parkinson\u2019s disease rat model. Vet World. 2018;11:1250\u20134.","journal-title":"Vet World"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01407-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01407-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01407-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:28:28Z","timestamp":1704191308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01407-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01407-7","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"30 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}